Pay attention to Analyst Guidance: Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Incorporated (LGND) stock price moved -1.73% away from 20-Days Simple Moving Average, -4.41% from 50-Days Simple Moving Average and separated -36.92% from 200 Days Simple Moving Average. Ligand Pharmaceuticals Incorporated (LGND) reported gain 2.61% in recent buying and selling session with closing price of $ 116.31. The stock’s traded 0.58 million shares in session while it holds an average volume of 0.77 million shares. The LGND switched 18.01% away from its 52 week minimum and distanced -58.25% from its 52 week peak. The volatility change in the previous week has observed by 3.68% and experienced of 3.78% change in the last month.

The short ratio in the company’s stock is documented at 10.76 and the short float is around of 41.82%. Beta factor, which measures the riskiness of the security, was registered at 1.42. The Company kept a record of 19.76 million floated shares and 20.54 million shares outstanding. The average true range of the stock is observed at 4.86 and the relative strength index of the stock is recorded at 46.41.

Consensus Recommendation:

Analyst notified mean rating at 1.90 after consensus analysis. (Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Keep in mind that Investors should not rely only on an analyst’s recommendation when taking a decision whether to buy, hold, or sell a stock. Instead, they should also do their own research—such as reading the prospectus for new companies or for public companies, the quarterly and annual reports filed with the SEC—to confirm whether a particular investment is appropriate for them in light of their individual financial circumstances.

Ligand Pharmaceuticals Incorporated (LGND) Stock Profitability Levels:

Net profit margin of the company is seen at 57.00%. Operating profit margin is positioned at 65.10%. Gross profit margin is 97.50%. The larger the gross profit margin, the better for the company. The company made Return on equity of 24.10% in last 12 months period. Return on assets ratio of the Company was 9.60%. Its return on investment ratio was 11.20% in the trailing 12 months period.

The Company’s sales have grown at an average annualized rate of about 38.70% during the past five years. For the past 5 years, The Company’s EPS growth has been nearly 69.60%. Looking out over a next 5-year period, analysts expect the company to see its earnings go up by 25.00%, annually. Analyst established EPS growth expected to grow of 212.30% for this year and EPS growth for next year is likely to attain at -13.05%.

Looking about the past performance history, the company jumped 9.19% for the last five trades and exhausted -1.41% in one month period. The stock deteriorated -21.74% during the past three month period and discounted -54.62% in half year. During the yearly overview it downgraded -36.31% and shown -14.29% year to date performance.

Jose Gable

Jose Gable

Jose has a wide look on current Healthcare and biotech news and events. Jose has done its MBA in 1999 from U.S. National University. At our place, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Jose personal interests in health, fitness, animal care, gardening, travel, world politics, and current social issues, but always willing to learn something new. The more shareholders that are interested in the stock for reasons based on their respective investment mandates and the more likely it will move higher. Address: 3332 Farm Meadow Drive, Nashville, TN 37214 Phone: +1 931-236-3269 Email: Jose@talktraders.com